Your browser is no longer supported. Please, upgrade your browser.
Settings
BMRN BioMarin Pharmaceutical Inc. daily Stock Chart
BMRN [NASD]
BioMarin Pharmaceutical Inc.
Index- P/E- EPS (ttm)-0.61 Insider Own0.50% Shs Outstand170.74M Perf Week3.19%
Market Cap17.54B Forward P/E552.31 EPS next Y0.19 Insider Trans-27.08% Shs Float170.74M Perf Month14.17%
Income-107.20M PEG- EPS next Q-0.21 Inst Own- Short Float6.64% Perf Quarter24.24%
Sales1.38B P/S12.68 EPS this Y88.70% Inst Trans0.03% Short Ratio8.38 Perf Half Y13.87%
Book/sh15.96 P/B6.44 EPS next Y125.00% ROA-3.30% Target Price114.24 Perf Year12.89%
Cash/sh8.10 P/C12.68 EPS next 5Y- ROE-5.20% 52W Range75.81 - 103.96 Perf YTD15.21%
Dividend- P/FCF- EPS past 5Y14.70% ROI-1.30% 52W High-1.18% Beta1.61
Dividend %- Quick Ratio2.30 Sales past 5Y21.30% Gross Margin80.20% 52W Low35.51% ATR2.65
Employees2581 Current Ratio2.90 Sales Q/Q23.00% Oper. Margin-2.80% RSI (14)68.21 Volatility2.46% 3.07%
OptionableYes Debt/Eq0.42 EPS Q/Q-193.80% Profit Margin-10.50% Rel Volume0.69 Prev Close103.61
ShortableYes LT Debt/Eq0.29 EarningsAug 02 AMC Payout- Avg Volume1.35M Price102.73
Recom1.80 SMA205.99% SMA5011.24% SMA20017.51% Volume934,515 Change-0.85%
May-16-18Initiated Canaccord Genuity Buy $101
Jan-18-18Resumed Credit Suisse Outperform $113
Oct-06-17Resumed Goldman Buy $129
Sep-15-17Initiated RBC Capital Mkts Sector Perform $93
Sep-14-17Initiated Piper Jaffray Overweight $113
Aug-31-17Initiated Citigroup Buy $98
Aug-17-17Initiated Evercore ISI Outperform $100
Mar-30-17Initiated UBS Neutral $92
Mar-02-17Initiated Instinet Neutral $93
Feb-07-17Initiated Morgan Stanley Overweight $110
Jan-23-17Resumed Credit Suisse Outperform
Dec-08-16Initiated Gabelli & Co Buy $109
Nov-07-16Downgrade Piper Jaffray Overweight → Neutral
Nov-03-16Initiated Deutsche Bank Buy $106
Aug-05-16Reiterated Stifel Buy $107 → $113
Aug-05-16Reiterated Piper Jaffray Overweight $107 → $120
Mar-08-16Upgrade Robert W. Baird Neutral → Outperform $110
Mar-03-16Reiterated Stifel Buy $105 → $107
Feb-29-16Reiterated Wedbush Neutral $117 → $105
Feb-26-16Reiterated RBC Capital Mkts Outperform $155 → $125
Jul-11-18 08:30AM  BioMarin to Host Second Quarter 2018 Financial Results Conference Call and Webcast on Thursday, August 2 at 4:30pm ET PR Newswire
Jul-09-18 11:30AM  Gene Therapy: BioMarin, Spark Can Both Win Treating Hemophilia Barrons.com
08:30AM  BioMarin Partners with Believe Limited for 'Breaking Through!' Musical Theater Intensive PR Newswire
Jul-05-18 10:32AM  Sarepta's DMD Portfolio Solid, Sole Drug Dependence Concerns Zacks
Jul-03-18 05:11PM  Rare disease drug maker BioMarin's unusual path to campus expansion in Marin: Team up with a local senior center American City Business Journals
Jul-02-18 08:20AM  Today's Research Reports on Trending Tickers: BioMarin Pharmaceutical and Arena Pharmaceuticals ACCESSWIRE
Jun-28-18 08:30AM  BioMarin Announces First Recipients of RARE Scholars Scholarship Program PR Newswire
Jun-27-18 07:35AM  Report: Developing Opportunities within American Homes 4 Rent, Invitation Home, Graphic Packaging Holding, Flotek Industries, Sunstone Hotel Investors, and BioMarin Pharmaceutical Future Expectations, Projections Moving into 2018 GlobeNewswire
Jun-19-18 07:00AM  Free Technical Research on BioPharmX and Three More Biotech Equities bio ACCESSWIRE
Jun-18-18 08:46AM  BioMarin Pharmaceutical (BMRN) Catches Eye: Stock Jumps 8.5% Zacks
08:10AM  Todays Research Reports on Stocks to Watch: Geron Corporation and BioMarin Pharmaceutical ACCESSWIRE
Jun-15-18 10:52AM  BioMarin Begins Pediatric Study on Achondroplasia Candidate Zacks +8.47%
07:30AM  3 Biotech Stocks Up in the Past Month on Industry Turnaround InvestorPlace
Jun-14-18 08:30AM  BioMarin Doses First Participant in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia PR Newswire
Jun-07-18 09:45AM  Why I Just Bought These 3 Stocks Motley Fool
08:15AM  BioMarin Receives Milestone Payments from Pfizer for Talazoparib PR Newswire
Jun-05-18 10:10AM  3 Biotech Stocks Up in the Past Month on Industry Turnaround Zacks
May-31-18 04:56PM  Catalyst's Fridapse Gets Priority Review by FDA, Shares Up Zacks
11:23AM  5 Biotech Stocks to Boost Your Portfolios Health This Year InvestorPlace
May-30-18 08:34PM  Why this biotech exec broke down on a conference call over company's new rare-disease drug American City Business Journals
11:53AM  Probing the Long Side of BioMarin TheStreet.com
10:39AM  Allergan Recalls Taytulla Oral Contraceptives, Stock Down Zacks
08:26AM  Biotech Stock Roundup: GILD Epclusa's China Approval, BMRN Palynziq's FDA Nod Zacks
May-29-18 10:09AM  Here's Why Sarepta is Up More Than 60% So Far This Year Zacks
08:20AM  Todays Research Reports on Stocks to Watch: Ultragenyx Pharmaceutical and BioMarin Pharmaceutical ACCESSWIRE
May-26-18 08:05AM  Which Is the Best Hemophilia Stock to Buy Now? Motley Fool
07:15AM  This Rare-Disease Biotech Scores an Important Win Motley Fool
May-25-18 12:18PM  BioMarin's New Rare-Disease Med Costs 50% More Than Expected Investor's Business Daily
10:57AM  BioMarin's Palynziq Gets FDA Approval for Phenylketonuria Zacks
09:19AM  Benzinga's Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck's Cancer Drug Review Extended Benzinga
08:58AM  A rare, brain-damaging disease faces a new foe: a $267K-a-year drug from a Bay Area stalwart American City Business Journals
08:01AM  Stock Market Today: Track Market Trends And The Best Stocks To Watch Investor's Business Daily
May-24-18 10:41PM  FDA approves BioMarin rare metabolic disorder drug, shares rise Reuters
06:10PM  BioMarin shares rise on FDA approval of rare metabolic disorder drug MarketWatch
05:42PM  BioMarin Receives Standard Approval for Palynziq (pegvaliase-pqpz) Injection for Treatment of Adults with Phenylketonuria (PKU), a Rare Genetic Disease PR Newswire
May-23-18 10:30AM  A Big Decision Is Fast-Approaching for This Rare-Disease Drugmaker Motley Fool
May-22-18 04:25PM  Why Analysts Remain Bullish On This Hemophilia Gene-Therapy Play Investor's Business Daily
08:05AM  Benzinga's Daily Biotech Pulse: Melinta, Ardelyx Pull Back On Offerings, Insys Awaits FDA Verdict Benzinga
07:30AM  BioMarin Provides 2 Years of Clinical Data in 6e13 vg/kg Dose from Ongoing Phase 1/2 Study in Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at World Federation of Hemophilia 2018 World Congress PR Newswire
May-21-18 07:40AM  The Week Ahead In Biotech: PDUFA Dates, IPOs And More Benzinga
May-17-18 04:48PM  The FDA Is Trying To 'Shame' Celgene, Gilead Here's Why It Won't Work Investor's Business Daily
04:13PM  Gilead, BioMarin among Bay Area drug makers shamed by FDA in generics 'gaming' list American City Business Journals
04:05PM  BioMarin Announces 1 Platform and 3 Poster Presentations at World Federation of Hemophilia 2018 World Congress PR Newswire
May-16-18 09:59AM  BioMarin Begins Mid Stage Study on Gene Therapy Candidate Zacks
May-15-18 10:32AM  Merck KGaA (MKGAF) Q1 Earnings and Revenues Decline Y/Y Zacks
08:30AM  BioMarin Announces First Patient Dosed in Phase 1/2 Study Evaluating Valoctocogene Roxaparvovec Gene Therapy in Severe Hemophilia A Patients with Pre-existing AAV5 Antibodies PR Newswire
May-11-18 12:11PM  BioMarin Pharmaceutical Is Doing Better but Patience Is Needed TheStreet.com
11:03AM  Cramer says it's 'very hard to put a price on' lifesaving... CNBC Videos
08:00AM  Today's Research Reports on Trending Tickers: BioMarin Pharmaceutical and Omeros Corporation ACCESSWIRE
07:50AM  New Research: Key Drivers of Growth for Harley-Davidson, BioMarin Pharmaceutical, Acadia Healthcare, Parker Drilling, NCR, and New York Community Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
May-10-18 07:07PM  Our new drug could drastically change hemophilia patients... CNBC Videos
06:59PM  Cramer Remix: The one thing thats keeping the market from tanking CNBC
May-09-18 07:35AM  Our Free Research Report on Biogen and More Biotech Stocks ACCESSWIRE
May-07-18 04:04PM  Why Hemophilia Patients Could Pay $1.5 Million For Gene Therapy Investor's Business Daily
01:38PM  First US drug priced at more than $1 million may be on the horizon CNBC
May-02-18 08:30AM  BioMarin to Attend Upcoming Investor Conference PR Newswire
May-01-18 12:05PM  BioMarin Named To Forbes List Of America's Best Mid-size Employers PR Newswire
Apr-27-18 07:15PM  BioMarin Cruises While It Waits on Seventh Approval Motley Fool
07:30AM  Wired News Concert Pharma Enrolled Last Patient in Phase-2a Trial Evaluating CTP-543 in Alopecia Areata ACCESSWIRE
Apr-26-18 10:30AM  BioMarin (BMRN) Q1 Earnings Lower Than Expected, Sales Beat Zacks
08:07AM  Benzinga's Daily Biotech Pulse: Catabasis Soars On Trial Results, Eloxx Listing, Biomarin Earnings Benzinga
02:42AM  Edited Transcript of BMRN earnings conference call or presentation 25-Apr-18 8:30pm GMT Thomson Reuters StreetEvents
Apr-25-18 04:36PM  BioMarin: 1Q Earnings Snapshot Associated Press
04:05PM  BioMarin Announces First Quarter 2018 Financial Results PR Newswire
01:25PM  3 Charts That Suggest Biotech Stocks Are Headed Lower Investopedia
12:00PM  BioMarin Pharmaceutical Inc. to Host Earnings Call ACCESSWIRE
11:06AM  How Financially Strong Is BioMarin Pharmaceutical Inc (NASDAQ:BMRN)? Simply Wall St.
Apr-24-18 02:30PM  New England Journal of Medicine Published Open-label Study Showing Brineura® (cerliponase alfa) Reduced the Rate of Clinical Decline of Children with CLN2 Disease, a Form of Batten Disease PR Newswire
10:49AM  Chardan's Top Pick For 2018: Gene Therapy Firm Uniqure Benzinga
10:09AM  What's in the Cards for BioMarin (BMRN) in Q1 Earnings? Zacks
Apr-20-18 02:00PM  The Week Ahead In Biotech: PDUFA Dates, IPOs And More Benzinga
Apr-18-18 08:30AM  BioMarin to Host First Quarter 2018 Financial Results Conference Call and Webcast on Wednesday, April 25 at 4:30pm ET PR Newswire
Apr-16-18 08:17AM  The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte Zacks
Apr-13-18 10:06AM  Gene Therapy in Limelight on Novartis Deal: 3 Stocks in Focus Zacks
09:33AM  Pharma M&A Active This Week: 4 Potential Buyout Targets Zacks
08:30AM  Todays Research Reports on Trending Tickers: Array BioPharma and BioMarin Pharmaceutical ACCESSWIRE
08:07AM  Did BioMarin Pharmaceutical Incs (NASDAQ:BMRN) Earnings Growth Outperform The Industry? Simply Wall St.
Apr-11-18 06:00AM  10 Cheap, High-Quality Stocks With Major Growth Catalysts Morningstar
Apr-10-18 04:23PM  How These Gene Therapy Stocks Benefit From Novartis-AveXis Deal Investor's Business Daily
Apr-05-18 03:36PM  Catalyst (CPRX) Up on New Drug Application for Firdapse Zacks
Apr-03-18 03:48PM  Motley Fool 100 Update: What's In and What's Out Motley Fool
Apr-02-18 10:52AM  MARKETS: Why April could be a bad month for stocks Yahoo Finance Video
Mar-29-18 04:30PM  Roche Hashes Out Details Of Patient Deaths In Hemophilia Drug Investor's Business Daily
09:54AM  BioMarin's MAA for Phenylketonuria Candidate Gains EU Nod Zacks
Mar-28-18 04:05PM  European Medicines Agency (EMA) Accepts BioMarin's Marketing Application for Pegvaliase MAA for Treatment of Phenylketonuria (PKU) PR Newswire
Mar-26-18 01:22AM  BioMarin Pharmaceutical (BMRN) Down 3.1% Since Earnings Report: Can It Rebound? Zacks
Mar-23-18 05:58PM  BioMarin Pharmaceutical Incs (NASDAQ:BMRN) Path To Profitability Simply Wall St.
Mar-21-18 08:35AM  BioMarin's Gene Therapy Manufacturing Facility Recognized with Industry Award PR Newswire
Mar-07-18 06:00AM  10 Growth Stocks at Value Prices Morningstar
Mar-06-18 08:30AM  BioMarin to Attend Upcoming Investor Conference PR Newswire
Mar-01-18 11:51AM  Edited Transcript of BMRN earnings conference call or presentation 22-Feb-18 9:30pm GMT Thomson Reuters StreetEvents
Feb-28-18 08:30AM  Rare Disease Day 2018: BioMarin Launches RARE Scholars Scholarship Program PR Newswire
07:00AM  Productive Pipeline Positions BioMarin for Success Morningstar
Feb-27-18 07:20AM  Blog Exposure - CHMP Recommended Against Approval of Puma Biotech's Neratinib for Extended Adjuvant Treatment of HER2-Positive Breast Cancer ACCESSWIRE
Feb-26-18 09:48PM  Biomarin Pharmaceutical Inc (BMRN) Files 10-K for the Fiscal Year Ended on December 31, 2017 GuruFocus.com
04:25PM  BioMarin Turns a Profit (on an Adjusted Basis) Motley Fool
Feb-23-18 04:45PM  Is This Biotech Hedging Its 2018 Outlook On A Key FDA Approval? Investor's Business Daily
11:52AM  Why Leerink Adjusted Upside Expectations For 3 Biotechs Benzinga
09:12AM  BioMarin (BMRN) Q4 Loss Wider Than Expected, Sales Beat Zacks
Feb-22-18 04:32PM  BioMarin reports 4Q loss Associated Press
BioMarin Pharmaceutical, Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome. The company's commercial products also comprise Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes pegvaliase, an enzyme substitution therapy for the treatment of phenylketonuria; vosoritide, a peptide therapeutic for the treatment of achondroplasia, a form of disproportionate short stature in humans; valoctocogene roxaparvovec, an AAV5 vector and factor VIII gene therapy drug development candidate for the treatment of severe hemophilia A; BMN 250, an investigational enzyme replacement therapy for the treatment of Sanfilippo Syndrome Type B or mucopolysaccharidosis type IIIB; and BMN 290, a selective chromatin modulation therapy for the treatment of Friedreich's ataxia. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration agreements with Sarepta Therapeutics and Genzyme Corporation; and a license agreement with Asubio Pharma Co., Ltd. The company was founded in 1996 and is headquartered in San Rafael, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LAWLIS V BRYANDirectorJun 27Option Exercise14.392,15030,93921,310Jun 29 05:59 PM
LAWLIS V BRYANDirectorJun 27Sale93.522,150201,06819,160Jun 29 05:59 PM
Mueller BrianSVP, Corporate ControllerJun 22Option Exercise28.232,49170,32114,866Jun 26 08:15 PM
BAFFI ROBERTEVP, Technical OperationsJun 22Option Exercise14.396,94999,99690,225Jun 26 08:23 PM
BAFFI ROBERTEVP, Technical OperationsJun 22Sale99.006,949687,95483,276Jun 26 08:23 PM
Mueller BrianSVP, Corporate ControllerJun 22Sale99.503,145312,92812,375Jun 26 08:15 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerJun 22Sale99.0010,000990,00551,070Jun 26 08:31 PM
Mueller BrianSVP, Corporate ControllerJun 15Sale94.502,021190,98513,029Jun 18 08:30 PM
FUCHS HENRY JPresident, Worldwide R&DJun 14Option Exercise34.4331,0001,067,380175,848Jun 18 08:11 PM
FUCHS HENRY JPresident, Worldwide R&DJun 14Sale90.0031,0002,790,085155,167Jun 18 08:11 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 13Option Exercise14.391,00014,390285,290Jun 14 07:53 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerJun 11Sale90.311,436129,68550,135Jun 13 06:49 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 17Option Exercise38.5918,750723,563309,350May 18 06:15 PM
MEIER RICHARD ADirectorMay 17Option Exercise38.5915,000578,85051,310May 18 06:33 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 17Sale88.6618,7501,662,356290,600May 18 06:15 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 16Option Exercise38.5918,750723,563309,350May 17 08:03 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 16Sale89.1318,7501,671,131290,600May 17 08:03 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 15Option Exercise38.5918,750723,563309,350May 16 06:30 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 15Sale88.2918,7501,655,434290,600May 16 06:30 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 14Option Exercise38.5918,750723,563309,350May 16 06:30 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 14Sale89.2218,7501,672,851290,600May 16 06:30 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 11Option Exercise38.5918,750723,563309,350May 14 09:28 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 11Sale88.4218,7501,657,856290,600May 14 09:28 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 10Option Exercise38.5918,750723,563309,350May 14 09:28 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 10Sale89.5918,7501,679,794290,600May 14 09:28 PM
Mueller BrianSVP, Corporate ControllerMay 10Sale89.502,450219,27515,396May 14 08:43 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMay 07Sale85.9630926,56252,914May 09 06:41 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 24Option Exercise38.5910,000385,900300,031Apr 25 08:30 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 24Sale82.2910,000822,887290,031Apr 25 08:30 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 23Option Exercise38.5910,000385,900300,031Apr 25 08:30 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerApr 23Sale82.1511,059908,49762,543Apr 25 08:37 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 23Sale82.5810,000825,811290,031Apr 25 08:30 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 20Option Exercise38.5910,000385,900300,031Apr 24 07:50 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 20Sale83.6510,000836,458290,031Apr 24 07:50 PM
LAWLIS V BRYANDirectorApr 17Option Exercise38.593,750144,71318,610Apr 19 07:19 PM
LAWLIS V BRYANDirectorApr 17Sale85.003,750318,75014,860Apr 19 07:19 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 05Option Exercise14.391,00014,390290,031Apr 09 03:51 PM
FUCHS HENRY JPresident, Worldwide R&DApr 02Option Exercise33.7910,000337,851163,326Apr 03 08:51 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 02Option Exercise14.391,00014,390289,031Apr 03 08:56 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerApr 02Sale80.122,119169,77452,914Apr 03 09:00 PM
FUCHS HENRY JPresident, Worldwide R&DApr 02Sale80.1210,000801,200156,676Apr 03 08:51 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 29Sale79.691,537122,48455,033Mar 30 08:03 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 28Option Exercise16.132,00032,250288,031Mar 30 07:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 27Option Exercise14.391,00014,390286,031Mar 28 06:36 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 26Option Exercise14.391,00014,390285,031Mar 28 06:36 PM
Davis George EricEVP, General CounselMar 23Sale81.353,350272,52387,989Mar 27 06:17 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 22Option Exercise14.391,00014,390297,106Mar 26 07:27 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 21Sale83.904,368366,47560,153Mar 23 04:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 16Option Exercise38.5915,000578,850311,106Mar 20 07:46 PM
Davis George EricEVP, General CounselMar 16Sale83.883,818320,25494,634Mar 20 07:36 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 16Sale83.2615,0001,248,854296,106Mar 20 07:46 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 15Option Exercise38.5915,000578,850279,674Mar 20 02:16 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 15Sale84.7315,0001,270,901264,674Mar 20 02:16 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 09Sale82.392,972244,86355,332Mar 13 08:31 PM
Davis George EricEVP, General CounselMar 05Sale79.042,105166,37990,089Mar 07 06:06 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 02Option Exercise14.391,00014,390273,216Mar 06 08:55 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 15Option Exercise38.5910,000385,900236,494Feb 20 08:40 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 15Sale84.6310,000846,285226,494Feb 20 08:40 PM
Davis George EricEVP, General CounselFeb 01Option Exercise38.5930,0001,157,700112,942Feb 05 08:13 PM
Davis George EricEVP, General CounselFeb 01Sale90.6630,0002,719,66582,942Feb 05 08:13 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 05Option Exercise38.5910,000385,900235,894Jan 09 08:36 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 05Sale90.3210,000903,203225,894Jan 09 08:36 PM
FUCHS HENRY JPresident, Worldwide R&DJan 02Option Exercise33.8015,000507,050148,976Jan 04 07:26 PM
LAWLIS V BRYANDirectorJan 02Option Exercise38.593,750144,71318,610Jan 04 08:16 PM
LAWLIS V BRYANDirectorJan 02Sale88.843,750333,15014,860Jan 04 08:16 PM
FUCHS HENRY JPresident, Worldwide R&DJan 02Sale89.2315,0001,338,401133,976Jan 04 07:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 29Option Exercise38.5910,000385,900235,894Jan 02 05:29 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 29Sale89.6110,000896,125225,894Jan 02 05:29 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 28Option Exercise38.5910,000385,900235,894Jan 02 05:29 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 28Sale89.8910,000898,912225,894Jan 02 05:29 PM
HERON ELAINE JDirectorDec 14Sale88.9080071,11638,385Dec 18 08:56 PM
Davis George EricEVP, General CounselNov 30Sale85.641,200102,76782,942Dec 04 08:26 PM
BAFFI ROBERTEVP, Technical OperationsSep 28Sale92.062,915268,35528,761Oct 02 09:07 PM
BAFFI ROBERTEVP, Technical OperationsSep 28Sale92.5015,5001,433,676129,083Oct 02 09:07 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerSep 22Option Exercise37.463,521131,89750,110Sep 26 07:19 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerSep 22Sale95.003,521334,49547,944Sep 26 07:19 PM
FUCHS HENRY JPresident, Worldwide R&DSep 15Option Exercise33.8015,000507,050151,422Sep 19 03:17 PM
LAWLIS V BRYANDirectorSep 15Option Exercise38.593,750144,71319,660Sep 19 03:27 PM
LAWLIS V BRYANDirectorSep 15Sale91.263,750342,22515,910Sep 19 03:27 PM
FUCHS HENRY JPresident, Worldwide R&DSep 15Sale90.5015,0001,357,500136,422Sep 19 03:17 PM